EV-based Omics Analysis Enabling Personalized Diagnosis
Tony Hu,
Professor and Presidential Chair,
Tulane University School of Medicine
Diagnostics for infectious and malignant diseases often exhibit poor specificity/sensitivity, hindering early detection and treatment evaluation, but development of improved assays is limited by several challenges, including absence of disease-specific factors, low biomarker concentrations, and interfering factors. We have employed an array of sensitive analytic technology platforms to identify key host-pathogen interactions that influence pathogenesis and applies this information to identify diagnostic and predictive biomarkers that can be applied for personalized medicine to improve patient outcomes. We reported the development and validation of several nanotechnoloy-based assays platforms that can be used to quantify protein and nucleic acid changes in EV-associated protein biomarkers, and which have the capacity to target EVs derived from specific cell populations, including EVs derived from Mtb-infected phagocytes and other cell populations involved in granuloma formation. Candidate biomarkers identified will be analyzed using these platforms and correlated with changes in specific granuloma and systemic cell populations.
|
|
